5-hydroxytryptamine (5-HT) receptor ligands.

Serotonin (5-HT) receptors are part of the G protein-coupled and ligand-gated ion channel families. 5-HT exerts its diverse actions by binding to cell surface receptors which can be classified into seven distinct families (5-HT1 to 5-HT7) according to their structural diversity and mode of action. Some of the 5-HT families are comprised of multiple receptors which share similar structural and mechanistic properties but display very different operational profiles. Evidence continues to mount in support of the important roles of the 5-HT receptors in various neuropsychiatric disorders such as anxiety, depression, schizophrenia, migraine and drug addiction. The 5-HT receptors may also play an important role in obesity, aggression, sexual behaviour and cardiovascular disorders. A number of selective/non-selective 5-HT agonist and antagonist ligands (drugs) have been developed to challenge many of these disease states.

[1]  D. Nelson,et al.  Molecular cloning, functional expression, and pharmacological characterization of a novel serotonin receptor (5-hydroxytryptamine2F) from rat stomach fundus. , 1992, Molecular pharmacology.

[2]  Alicja Lerner,et al.  Serotonin transporter: gene, genetic disorders, and pharmacogenetics. , 2004, Molecular interventions.

[3]  P. Pauwels,et al.  Molecular cloning and expression of the porcine trigeminal ganglion cDNA encoding a 5-ht1F receptor , 2002 .

[4]  J. Kehne,et al.  Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. , 1993, The Journal of pharmacology and experimental therapeutics.

[5]  J. Holenz,et al.  Medicinal chemistry strategies to 5-HT(6) receptor ligands as potential cognitive enhancers and antiobesity agents. , 2006, Drug discovery today.

[6]  I. Forbes,et al.  In vitro and in vivo profile of SB 206553, a potent 5‐HT2C/5‐HT2B receptor antagonist with anxiolytic‐like properties , 1996, British journal of pharmacology.

[7]  Gavin Kilpatrick,et al.  5‐HT3 receptors , 1990, Annals of the New York Academy of Sciences.

[8]  H. Lester,et al.  The role of conserved aspartate and serine residues in ligand binding and in function of the 5‐HT1A receptor: A site‐directed mutation study , 1992, FEBS letters.

[9]  J Hoflack,et al.  Modeling of G-protein-coupled receptors: application to dopamine, adrenaline, serotonin, acetylcholine, and mammalian opsin receptors. , 1992, Journal of medicinal chemistry.

[10]  M. Caron,et al.  The genomic clone G-21 which resembles a β-adrenergic receptor sequence encodes the 5-HT1A receptor , 1988, Nature.

[11]  P P Humphrey,et al.  International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). , 1994, Pharmacological reviews.

[12]  P. Pauwels,et al.  Donitriptan, a Unique High-Efficacy 5-HT1B/1D Agonist: Key Features and Acute Antimigraine Potential , 2006 .

[13]  K. Dev,et al.  Functional expression of the serotonin 5‐HT7 receptor in human glioblastoma cell lines , 2004, British journal of pharmacology.

[14]  M. Koyama,et al.  Synthesis, SAR studies, and evaluation of 1,4-benzoxazepine derivatives as selective 5-HT1A receptor agonists with neuroprotective effect: Discovery of Piclozotan. , 2006, Bioorganic & medicinal chemistry.

[15]  Bryan L. Roth,et al.  WAY-100635 is a potent dopamine D4 receptor agonist , 2006, Psychopharmacology.

[16]  S. Cheetham,et al.  Evidence that RU 24969‐induced locomotor activity in C57/B1/6 mice is specifically mediated by the 5‐HT1B receptor , 1993, British journal of pharmacology.

[17]  R. Balaraman,et al.  Antihypertensive Effect of 5-HT1A Agonist Buspirone and 5-HT2B Antagonists in Experimentally Induced Hypertension in Rats , 2005, Pharmacology.

[18]  T. Branchek,et al.  Human gene S31 encodes the pharmacologically defined serotonin 5-hydroxytryptamine1E receptor. , 1992, Molecular pharmacology.

[19]  R M Eglen,et al.  RS‐127445: a selective, high affinity, orally bioavailable 5‐HT2B receptor antagonist , 1999, British journal of pharmacology.

[20]  P. Pauwels,et al.  G‐protein activation at 5‐HT1A receptors by the 5‐ht1F ligand LY334370 in guinea‐pig brain sections and recombinant cell lines , 1998, British journal of pharmacology.

[21]  R. Vickery,et al.  The 5‐HT4 receptor agonist, tegaserod, is a potent 5‐HT2B receptor antagonist in vitro and in vivo , 2004, British journal of pharmacology.

[22]  S. Hjorth,et al.  8-Hydroxy-2-(di-n-propylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist. , 1981, Journal of medicinal chemistry.

[23]  A. Ramage.  The role of central 5‐hydroxytryptamine (5‐HT, serotonin) receptors in the control of micturition , 2006, British journal of pharmacology.

[24]  M. Rapport,et al.  Serum vasoconstrictor, serotonin; chemical inactivation. , 1948, The Journal of biological chemistry.

[25]  P. Pauwels,et al.  F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine. , 1999, The Journal of pharmacology and experimental therapeutics.

[26]  P. Pauwels.  5-HT 1B/D receptor antagonists. , 1997, General pharmacology.

[27]  P. Goadsby.  Can we Develop Neurally Acting Drugs for the Treatment of Migraine? , 2005, Nature Reviews Drug Discovery.

[28]  J. Holenz,et al.  Chronic 5‐HT6 receptor modulation by E‐6837 induces hypophagia and sustained weight loss in diet‐induced obese rats , 2006, British journal of pharmacology.

[29]  J. Palacios,et al.  Serotonin receptors in the human brain. II. Characterization and autoradiographic localization of 5-HT1C and 5-HT2 recognition sites , 1986, Brain Research.

[30]  Y. Uezono,et al.  Gq protein-coupled receptors as targets for anesthetics. , 2006, Current pharmaceutical design.

[31]  A. Green.  Neuropharmacology of 5-hydroxytryptamine. , 2006, British journal of pharmacology.

[32]  N. Sato,et al.  Synthesis and pharmacological evaluation of benzamide derivatives as selective 5-HT4 receptor agonists , 2005 .

[33]  C. Schneider,et al.  Interaction of arylpiperazine ligands with the hydrophobic part of the 5-HT1A receptor binding site. , 2006, Bioorganic & medicinal chemistry.

[34]  S. Watts.  5-HT in systemic hypertension: foe, friend or fantasy? , 2005, Clinical science.

[35]  T. Blackburn,et al.  BW 723C86, a 5-HT2B Receptor Agonist, Causes Hyperphagia and Reduced Grooming in Rats , 1997, Neuropharmacology.

[36]  A. Dowson,et al.  Review of zolmitriptan and its clinical applications in migraine , 2002, Expert opinion on pharmacotherapy.

[37]  B. Gulyás,et al.  N-oxide analogs of WAY-100635: new high affinity 5-HT(1A) receptor antagonists. , 2005, Bioorganic & medicinal chemistry.

[38]  W J Riedel,et al.  Serotonin and human cognitive performance. , 2006, Current pharmaceutical design.

[39]  Amitabha Chattopadhyay,et al.  The Serotonin1A A Receptor: A Representative Member of the Serotonin Receptor Family , 2005, Cellular and Molecular Neurobiology.

[40]  I. Page,et al.  Serotonin content of some mammalian tissues and urine and a method for its determination. , 1953, The American journal of physiology.

[41]  Trevor Sharp,et al.  A review of central 5-HT receptors and their function , 1999, Neuropharmacology.

[42]  Michael A. Briggs,et al.  Bicyclic heteroarylpiperazines as selective brain penetrant 5-HT6 receptor antagonists. , 2005, Bioorganic & medicinal chemistry letters.

[43]  D. Middlemiss,et al.  Pharmacological characterisation of human 5-HT2 receptor subtypes. , 2001, European journal of pharmacology.

[44]  J. Stamford,et al.  Multiple 5-HT1 autoreceptor subtypes govern serotonin release in dorsal and median raphé nuclei , 2001, Neuropharmacology.

[45]  S H Snyder,et al.  Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol. , 1979, Molecular pharmacology.

[46]  D. Hoyer,et al.  Molecular pharmacology of 5-HT1 and 5-HT2 recognition sites in rat and pig brain membranes: radioligand binding studies with [3H]5-HT, [3H]8-OH-DPAT, (-)[125I]iodocyanopindolol, [3H]mesulergine and [3H]ketanserin. , 1985, European journal of pharmacology.

[47]  A. Sleight,et al.  O-methylasparvenone, a nitrogen-free serotonin antagonist. , 1997, Bioorganic & medicinal chemistry.

[48]  A. Maassenvandenbrink,et al.  Donitriptan, but not sumatriptan, inhibits capsaicin‐induced canine external carotid vasodilatation via 5‐HT1B rather than 5‐HT1D receptors , 2006, British journal of pharmacology.

[49]  P. Whitaker-Azmitia.  The Discovery of Serotonin and its Role in Neuroscience , 1999, Neuropsychopharmacology.

[50]  A. Orjales,et al.  Synthesis and pharmacological characterization of a new benzoxazole derivative as a potent 5-HT3 receptor agonist. , 2003, Bioorganic & medicinal chemistry.

[51]  Kirk W. Johnson,et al.  Novel potent 5-HT(1F) receptor agonists: structure-activity studies of a series of substituted N-[3-(1-methyl-4-piperidinyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]amides. , 2003, Journal of medicinal chemistry.